EGFR and colorectal carcinoma: Similarly, cetuximab, which targets the epidermal growth factor receptor (EGFR), enhances the effect of RSL3 in inducing ferroptosis in KRAS-mutant CRC cells by activating p38 MAPK and inhibiting the NRF2/HO-1 axis [40].